Myriad Genetics will release its fourth quarter and full year 2025 financial results on February 23, 2026, the company announced. The release comes as the molecular diagnostics firm advances its Precise MRD product toward a targeted March 2026 launch, marking a significant expansion of its oncology portfolio.
The company has disclosed select preliminary financial metrics for the periods and provided forward guidance for 2026. Recent clinical data from breast and colorectal cancer studies demonstrated the Precise MRD platform's capabilities in ultrasensitive circulating tumor DNA detection, supporting the commercialization timeline for the product.
The upcoming earnings report will provide investors with comprehensive details on full year 2025 operational and financial performance, while the Precise MRD launch represents a key growth initiative for Myriad as it expands beyond its current molecular diagnostics offerings.